Aclaris Therapeutics Inc., of Wayne, Pa., appointed David Gordon chief medical officer.
Aerie Pharmaceuticals Inc., of Durham, N.C., appointed William Coppola intellectual property counsel.
Albireo Pharma Inc., of Boston, appointed Jason G. Duncan general counsel and secretary.
Allergan plc, of Dublin, appointed Thomas C. Freyman to its board.
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., appointed Masako Nakamura senior vice president, head of Asia, and Jing L. Marantz senior vice president, head of medical affairs.
Anokion SA, of Ecublens, Switzerland, appointed Deborah Geraghty chief business officer, Stephan Kontos, chief scientific officer, Tony Rossomando vice president, technical operations and Michael Clayman chair of its board.
Atossa Genetics Inc., of Seattle, appointed Makarand (Mak) Jawadekar and Ajit Shetty to its strategic advisory board.
Bioxcel Therapeutics Inc., of Branford, Conn., appointed Cedric Burg vice president and head of global clinical operations and project management.
Celgene Corp., of Summit, N.J., appointed Jonathan Biller executive vice president and general counsel, effective July 3.
Collplant Ltd., of Ness Ziona, Israel, appointed Shay Soker to its scientific advisory board.
Crescendo Biologics Ltd., of Cambridge, U.K., appointed Eva-Lotta Allan non-executive director.
Crinetics Pharmaceuticals Inc., of San Diego, appointed Alan Krasner chief medical officer.
Cytomx Therapeutics Inc., of South San Francisco, appointed Lloyd A. Rowland, Jr. senior vice president, general counsel.
Eloxx Pharmaceuticals Inc., of Waltham, Mass., appointed Neil Belloff executive vice president, general counsel and corporate secretary.
Ethypharm SA, of Saint-Cloud, France, appointed Frédéric Molin executive vice president corporate development.
Evolus Inc., of Irvine, Calif., appointed Michael Mazen Jafar chief marketing officer.
Gammadelta Therapeutics Ltd., of London, appointed Michael Koslowski chief medical officer.
IFM Therapeutics Inc., of Boston, appointed Jasmin Kümmerle-Deschner, Peter Libby, Giovanni Monteleone, Markus F. Neurath, D. Brent Polk, David T. Rubin, Arun J. Sanyal and Scott B. Snapper to its clinical advisory board.
Innovate Biopharmaceuticals Inc., of Raleigh, N.C., appointed Saira Ramasastry to its board.
JHL Biotech Co. Ltd., of Hsinchu, Taiwan, appointed Ellis Chu chief financial officer.
Kura Oncology Inc., of San Diego, appointed John Farnam chief operating officer, and Bridget Martell and Blake Tomkinson vice presidents of clinical development.
Marina Biotech Inc., of City of Industry, Calif., appointed Robert C. Moscato, Jr. CEO.
Mesoblast Ltd., of Melbourne, Australia, appointed Joseph Swedish to its board.
Nantkwest Inc., of Culver City, Calif., appointed Sonja Nelson chief financial officer.
Numedii Inc., of San Mateo, Calif., appointed Athena M. Countouriotis to its board and Zemin Zhang to its scientific advisory board.
Oncobiologics Inc., of Cranbury, N.J., appointed Randy Thurman executive chair of its board and Lawrence A. Kenyon interim CEO.
Orbis Biosciences Inc., of Lenexa, Kan., appointed Karl Strohmeier chief licensing officer and Brad Spitz vice president of business development.
Sanofi SA, of Paris, appointed Jean-Baptiste Chasseloup de Chatillon executive vice president, chief financial officer and member of the executive committee, effective Oct. 1.
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, appointed Tetsuya Uyama, senior officer, legal disputes and Hiroshi Kishimoto, senior director, legal affairs, both effective July 1.
Syros Pharmaceuticals Inc., of Cambridge, Mass., appointed Michael W. Bonney to its board.
Therapeutic Solutions International Inc., of Oceanside, Calif., appointed James Veltmeyer chief medical officer.